Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 646

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial

Vandenberghe, Rik, Van Laere, Koen, Ivanoiu, Adrian, Salmon, Eric, Bastin, Christine, Triau, Eric, Hasselbalch, Steen, Law, Ian, Andersen, Allan, Korner, Alex, Minthon, Lennart, Garraux, Gaëtan, Nelissen, Natalie, Bormans, Guy, Buckley, Chris, Owenius, Rikard, Thurfjell, Lennart, Farrar, Gill, Brooks, David J.·2010·Annals of Neurology

Abstract

Objective: The most widely studied positron emission tomography ligand for in vivo β‐amyloid imaging is 11 C‐Pittsburgh compound B (11 C‐PIB). Its availability, however, is limited by the need for an on‐site cyclotron. Validation of the 18 F‐labeled PIB derivative 18 F‐flutemetamol could significantly enhance access to this novel technology. Methods: Twenty‐seven patients with early‐stage clinically probable Alzheimer disease (AD), 20 with amnestic mild cognitive impairment (MCI), and 15 cognitively intact healthy volunteers (HVs) above and 10 HVs below 55 years of age participated. The primary endpoint was the efficacy of blinded visual assessments of 18 F‐flutemetamol scans in assigning subjects to a raised versus normal uptake category, with clinical diagnosis as the standard of truth (SOT). As secondary objectives, we determined the correlation between the regional standardized uptake value ratios (SUVRs) for 18 F‐flutemetamol and its parent molecule 11 C‐PIB in 20 of the AD subjects and 20 of the MCI patients. We also determined test‐retest variability of 18 F‐flutemetamol SUVRs in 5 of the AD subjects. Results: Blinded visual assessments of 18 F‐flutemetamol scans assigned 25 of 27 scans from AD subjects and 1 of 15 scans from the elderly HVs to the raised category, corresponding to a sensitivity of 93.1% and a specificity of 93.3% against the SOT. Correlation coefficients between cortical 18 F‐flutemetamol SUVRs and 11 C‐PIB SUVRs ranged from 0.89 to 0.92. Test‐retest variabilities of regional SUVRs were 1 to 4%. Interpretation: 18 F‐Flutemetamol performs similarly to the 11 C‐PIB parent molecule within the same subjects and provides high test‐retest replicability and potentially much wider accessibility for clinical and research use. ANN NEUROL 2010

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.22068

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 646

Metadata

Authors
Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., Hasselbalch, S., Law, I., Andersen, A., Korner, A., Minthon, L., Garraux, G., Nelissen, N., Bormans, G., Buckley, C., Owenius, R., Thurfjell, L., Farrar, G., & Brooks, D. J.
Venue
Annals of Neurology
Publisher
Wiley
Published
2010-08-30
Volume
68
Issue
3
Pages
319-329
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2074427084
Cited by
646
References
11
FWCI
28.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. https://app.cochat.ai/papers/10.1002/ana.22068
The paper
Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., Hasselbalch, S., Law, I., Andersen, A., Korner, A., Minthon, L., Garraux, G., Nelissen, N., Bormans, G., Buckley, C., Owenius, R., Thurfjell, L., Farrar, G., & Brooks, D. J. (2010). 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Annals of Neurology. https://doi.org/10.1002/ana.22068

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.